Bibliography
- Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008;65:1566-84
- Sebastian S, Settleman J, Reshkin SJ, et al. The complexity of targeting EGFR signaling in cancer: from expression to turnover. Biochim Biophys Acta 2006;1766:120-39
- Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16
- Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232
- Ferguson KM. Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 2008;37:353-73
- Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37
- Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non–small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92
- Weihua Z, Tsan R, Huang WC, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008;13:385-93
- Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 2006;11:905-10
- Ladner RC, Sato AK, Gorzelany J, de Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 2004;9:525-9
- Fricker G, Drewe J. Current concepts in intestinal peptide absorption. J Pept Sci 1996;2:195-211
- Sgambato A, Casaluce F, Maione P, et al. Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown? J Thorac Dis 2014;6(6):578-80
- Soeda H, Shimodaira H, Gamoh M, et al. Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801). Oncology 2014;87(1):7-20
- Sclafani F, Gonzalez D, Cunningham D, et al. TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. J Natl Cancer Inst 2014;106(7)
- Hamzeh-Mivehroud M, et al. Identification of new peptide ligands for epidermal growth factor receptor using phage display and computationally modeling their mode of binding. Chem Biol Drug Des 2012;79:246-59
- Azzazy HM, Highsmith WE. Phage display technology: clinical applications and recent innovations. Clin Biochem 2002;35:425-45
- Pande J, Szewczyk MM, Grover AK. Phage display: concept, innovations, applications and future. Biotechnol Adv 2010;28:849-58
- Lowman HB. Bacteriophage display and discovery of peptide leads for drug development. Annu Rev Biophys Biomol Struct 1997;26:401-24
- Christensen DJ, Gottlin EB, Benson RE, Hamilton PT. Phage display for target-based antibacterial drug discovery. Drug Discov Today 2001;6:721-7
- Smith GP, Petrenko VA. Phage display. Chem Rev 1997;97:391-410
- Noren KA, Noren CJ. Construction of high-complexity combinatorial phage display peptide libraries. Methods 2001;23:169-78
- Sidhu SS. Phage display in pharmaceutical biotechnology. Curr Opin Biotechnol 2000;11:610-16
- Chen Y, Shen Y, Guo X, et al. Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol 2006;24(4):455-60
- Kankia S, Jaalouka DE, Lee S, et al. Identification of targeting peptides for ischemic myocardium by in vivo phage display. J Mol Cell Cardiol 2011;50(5):841-8
- Sanchez AB, Nguyen T, Nguyen T, et al. A general process for the development of peptide-based immunoassays for monoclonal antibodies. Cancer Chemother Pharmacol 2010;66(5):919-25
- Lee L, Buckley C, Blades MC, et al. Identification of synovium-specific homing peptides by in vivo phage display selection. Arthritis Rheum 2002;46(8):2109-20
- Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and proteins. Crit Rev Ther Drug Carrier Syst 2003;20:153-214
- Hamman JH, Enslin GM, Kotzé AF. Oral delivery of peptide drugs. BioDrugs 2005;19(3):165-77